Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib + CLAG-M in Relapsed/Refractory FLT3-mutated AML
NCT05330377Phase 1Withdrawn
- Start
- Mar 2023
- Primary completion
- May 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of gilteritinib in acute myeloid leukemia (AML). Primary endpoints: Dose-limiting toxicities at 42 days and Maximum Tolerated Dose at 42 days. Planned start Mar 2023; status: withdrawn.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05330377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330377.